Hematology/Oncology Outcomes

Skip Navigation
Back to top

Why Choose Us: Nemours Center for Cancer and Blood Disorders

Our Outcomes: The Results of Our Care

The Nemours Center for Cancer and Blood Disorders (NCCBD) is a multisite center actively involved in the National Cancer Institute Community Oncology Research Program (NCORP). This means we offer state-of-the-art therapies for children with cancer — and we register our results in a national database to help improve treatment for kids everywhere.

The NCCBD leads and participates in many research programs, and measures a variety of outcomes. Two particular outcomes — acute leukemia survival rates and clinical trial accruals (patient placement into clinical trials) — are important indicators of our tireless efforts to find cures for even the most complex diseases.

Our results show that we help children with leukemia not just live, but live better. Also, as compared to the top five pediatric hematology/oncology programs in the country, we register and treat far more children in National Cancer Institute-sponsored research trials. These trials provide the foundation for progress and improved outcomes.

Why Measuring Results Matters

To provide pediatric care that is among the safest and most caring, we measure our results and compare them to national pediatric rates. Why? So we can:

  • help you make decisions about your child’s care
  • be clear about our results
  • improve and consistently deliver better, safer care

At Nemours we're doing better than the national average in many areas of cancer and blood disorder care.

 

Helping Kids With Acute Leukemia Not Just Live, But Live Better

Helping Kids With Acute Leukemia Not Just Live, But Live Better


Nemours' Overall Pediatric Leukemia 10-Year Survival Rate Better Than National Average

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) survival rates vary because the diseases involve different cell types and have different complications. With ALL, the most common childhood leukemia, surviving after five years is considered a cure because the disease rarely recurs (comes back).

The national five-year survival rate for ALL is 90.4 percent. That means about 90 out of 100 children diagnosed with ALL will survive five years after their diagnosis. For AML, the second most commonly diagnosed leukemia in children, the national 10-year survival rate is 57 percent. At Nemours, our patients’ survival rate is higher (better) than the national average. That’s because we:

  • commit 100 percent of our research resources to helping children with childhood cancer and blood disorders
  • actively lead and participate in clinical trials for a wide variety of cancer and blood disorders in children
  • rigorously pursue clinical trial participants through a formal, focused effort
  • integrate expertise and best practices across our locations so that families can get the best care from the most qualified experts

 

Acute Lymphoblastic Leukemia (ALL) 10-Year Survival

94%

Nemours Center for Cancer and Blood Disorders (All Locations), 2006-2016

90%

National Average (Benchmark)

 

Acute Myeloid Leukemia (AML) 10-Year Survival

60%

Nemours Center for Cancer and Blood Disorders (All Locations), 2006-2016

57%

National Average (Benchmark)

 

Data source: Nemours data from the cancer registry 2006-2016 from four key NCCBD sites: Nemours/Alfred I. duPont Hospital for Children (Wilmington, Del.), Nemours Children’s Hospital (Orlando) and Nemours Children’s Specialty Care, Jacksonville (Jacksonville, Fla.). 
Benchmark: Data published by the Children’s Oncology Group for the same time period.

Registering & Treating More Kids in Research Studies

Registering & Treating More Kids in Research Studies


Getting More Children Signed Up for Clinical Trials to Improve Care and Quality of Life

Much of the progress in finding cures for childhood cancer and blood disorders comes from registering and enrolling patients in clinical trials (this is referred to as “clinical trial accruals”). Unfortunately, many clinical trials never finish due to lack of participation or other factors. Fewer clinical trials means lost opportunities to find better treatments and cures. Therapies studied in clinical trials may help more children live and live healthier, with fewer and less severe side effects — now and in the future.

Every year, we measure four key clinical trial accrual outcomes:

  1. new patient registration
  2. cancer registry participation
  3. therapeutic trail enrollment (to study treatment effectiveness)
  4. supportive care and observational trial enrollment (to reduce the short- and long-term effects of treatment)

At Nemours, we beat (and, in some cases, far exceed) the clinical trial accruals of the top-ranked pediatric hematology/oncology programs in the country. We do this through an integrated, organization-wide clinical trial research office with resources dedicated to clinical trial accrual.

 

New Patient Registrations

145

Nemours Center for Cancer and Blood Disorders (All Locations), 2016

125

Top-Ranked Pediatric Programs

 

Cancer Registry Enrollment

100

Nemours Center for Cancer and Blood Disorders (All Locations), 2016

90

Top-Ranked Pediatric Programs

 

Therapeutic Trials

60

Nemours Center for Cancer and Blood Disorders (All Locations), 2016

25

Top-Ranked Pediatric Programs

 

Supportive Care & Observation Trial Enrollment

225

Nemours Center for Cancer and Blood Disorders (All Locations), 2016

150

Top-Ranked Pediatric Programs

 

Data source: Nemours data collected from the CREDIT© database tracking clinical trial accruals for 2015, for four key NCCBD sites: Nemours/Alfred I. duPont Hospital for Children (Wilmington, Del.), Nemours Children’s Hospital (Orlando) and Nemours Children’s Specialty Care, Jacksonville (Jacksonville, Fla.).
Benchmark: Mean number of patients for the top five pediatric cancer centers. 

Our Differentiators: What Sets Nemours Center for Cancer and Blood Disorders Apart

Our Differentiators: What Sets Nemours Center for Cancer and Blood Disorders Apart


Why Choose Us

If your child has cancer or a blood disorder, you want to know they're in the best hands:

  • The Nemours Center for Cancer and Blood Disorders is one of the largest pediatric hematology/oncology programs in the country (when combining our patient numbers from our many Nemours locations in the North and South).
  • We are one of only two National Cancer Institute Community Oncology Research Programs in the nation dedicated exclusively to children. This means we are a fully-integrated network with recognized excellence in clinical research, patient care and quality improvement. Because our care and research go hand-in-hand, your child gets the newest evidenced-based treatments and techniques — and faster.
  • Our outcomes meet or exceed national benchmarks. When compared to the three top-rated children’s hospitals for hematology/oncology, our infection prevention and five-year cancer and bone marrow transplant survival rates are on par, or better.
  • Nemours hospitals are recognized as “Top Children’s Hospitals.” The Leapfrog Group named two of our four NCCBD locations among the best: Nemours Children’s Hospital in Orlando (2014 and 2016) and Nemours/Alfred I. duPont Hospital for Children (2012). The duPont Hospital for Children is ranked among the best children’s hospitals for pediatric oncology by U.S. News & World Report.
  • Our cross-campus collaboration extends our shared, specialized expertise to where you are. This means your child can get a second, third and fourth opinion without leaving home.

At Nemours we focus on proven approaches to reduce side effects and provide state-of-the-art therapies through more clinical trials. Our goal, in everything we do, is to improve the lives of kids with cancer today and, hopefully, for many tomorrows.

Learn More About the Nemours Center for Cancer and Blood Disorders »